Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Kehoe

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|November 23, 2015
Nintedanib and ovarian cancer: standardise surgery in trials?Sean Kehoe
Maturitas|October 5, 2014
Bevacizumab and treatment of cervical cancerSean Kehoe
The Lancet. Oncology|November 8, 2016
Olaparib and ovarian cancer-overall survival outcomesSean Kehoe
Maturitas|June 21, 2015
Screening for ovarian cancerSean Kehoe
Journal of Gynecologic Oncology|June 11, 2020
FIGO staging in ovarian carcinoma and histological subtypesSean Kehoe
Best Practice & Research. Clinical Obstetrics & Gynaecology|August 10, 2006
Treatments for gynaecological cancersSean Kehoe
BJOG : an International Journal of Obstetrics and Gynaecology|January 27, 2016
Opportunistic salpingectomy at benign gynaecological surgery for ovarian cancer prevention should be performed within a clinical trial: AGAINST: Can we afford to wait for the results?Sean Kehoe
Maturitas|June 1, 2010
Serum tumour markers in gynaecological cancersPakhee Aggarwal, Sean Kehoe
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|April 4, 2020
FIGO stage IIB cervical cancer prognostication in low-resource settingsSean Kehoe, Neerja Bhatla,
Current Oncology Reports|June 6, 2015
When is it safe to omit surgery in primary peritoneal cancer with small volume disease?Rachel Pounds, Sean Kehoe
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|November 23, 2015
Nintedanib and ovarian cancer: standardise surgery in trials?Sean Kehoe
Maturitas|October 5, 2014
Bevacizumab and treatment of cervical cancerSean Kehoe
The Lancet. Oncology|November 8, 2016
Olaparib and ovarian cancer-overall survival outcomesSean Kehoe
Maturitas|June 21, 2015
Screening for ovarian cancerSean Kehoe
Journal of Gynecologic Oncology|June 11, 2020
FIGO staging in ovarian carcinoma and histological subtypesSean Kehoe
Best Practice & Research. Clinical Obstetrics & Gynaecology|August 10, 2006
Treatments for gynaecological cancersSean Kehoe
BJOG : an International Journal of Obstetrics and Gynaecology|January 27, 2016
Opportunistic salpingectomy at benign gynaecological surgery for ovarian cancer prevention should be performed within a clinical trial: AGAINST: Can we afford to wait for the results?Sean Kehoe
Maturitas|June 1, 2010
Serum tumour markers in gynaecological cancersPakhee Aggarwal, Sean Kehoe
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|April 4, 2020
FIGO stage IIB cervical cancer prognostication in low-resource settingsSean Kehoe, Neerja Bhatla,
Current Oncology Reports|June 6, 2015
When is it safe to omit surgery in primary peritoneal cancer with small volume disease?Rachel Pounds, Sean Kehoe
Pageof 12